Author: OurCrowd

[Morphisec in Benzinga] Morphisec recognized as a Sample Vendor in Gartner® Emerging Tech: Security – Emergence Cycle for Automated Moving Target Defense Report

Jun 12, 2023 |

Securing operatBOSTON and BEER-SHEVA, Israel, June 12, 2023 /PRNewswire-PRWeb/ — Morphisec, the world’s leading provider of prevention-first endpoint security software, today announced its recognition as a sample vendor in Gartner Emerging Tech: Security — Emergence Cycle for Automated Moving Target Defense[1]. Automated Moving Target Defense (AMTD) technologies use polymorphism to move, change, obfuscate or morph attack surfaces to disrupt adversary cyber kill chains.ional technology (OT) creates unique challenges. Zero tolerance of downtime in factories, ports, banks, treatment plants, and other OT environments means that standard security practices like patch management or deploying protective solutions onto endpoints can be almost impossible to uphold. Read more...

Read More

[OncoHost in Onco’Zine] A multicomponent biomarker approach will shift cancer care

Jun 12, 2023 |

For many years we have been working towards creating a paradigm shift in cancer care, and precision oncology is rapidly evolving, with the potential to revolutionize our current standards and guidelines. But while we have made giant strides in our understanding of the disease, the current approach to biomarker development is still simplistic and fragmented, limiting our ability to understand the underlying biology of the patient’s cancer, tailor treatment to individual patients, monitor treatment response, detect early signs of relapse, and identify potential new targets for therapy. True precision oncology requires a comprehensive and integrated approach to biomarker development to really make a dent. Read...

Read More

[The Global Health Equity Fund in Sojitz] Sojitz signs memorandum of understanding for strategic alliance with HIROTSU Bioscience, WHO Foundation, OurCrowd and Global Health Equity Fund

Jun 12, 2023 |

June 12, 2023 Sojitz Corporation (“Sojitz”) signed a memorandum of understanding with HIROTSU Bioscience Inc.(“HIROTSU”), a developer and provider of N-NOSE®, a primary cancer screening test is a revolutionary offering for early cancer detection, the WHO Foundation (“WHO Foundation”), OurCrowd, a venture capital firm and the Global Health Equity Fund (“GHEF”), a fund that invests in innovative new medical technologies to tackle health inequity to jointly conduct strategic alliances and feasibility studies for the deployment of N-NOSE® in low and middle-income countries and regions. Read more...

Read More

[Stellar Cyber in Business Wire] Stellar Cyber and Mimecast partner to deliver automated, scalable phishing attack mitigation solution

Jun 12, 2023 |

SAN JOSE, Calif.–(BUSINESS WIRE)–Stellar Cyber, the innovator of Open XDR, today announced a new technology partnership with Mimecast, an advanced email and collaboration security company. This powerful technology integration makes it easy for Stellar Cyber and Mimecast customers to swiftly mitigate the risk of damaging email-based attacks, such as phishing attacks, by automating the sharing of vital attack data between the two solutions, reducing attacker dwell time and speeding response. Read more...

Read More